Every 424B that OKYO Pharma Limited (OKYO) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow OKYO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full OKYO filings page.
OKYO Pharma Limited is offering 10,815,000 ordinary shares at $1.85 per share, raising about $20.0 million before underwriting fees. An additional 1,622,250 shares may be sold if the underwriters exercise their 30‑day option in full.
OKYO expects net proceeds of approximately $18.5 million, which it plans to use for clinical development of its product candidates, general corporate purposes and working capital. Shares outstanding will rise to 51,370,197 (or 52,992,447 if the option is fully exercised), creating immediate dilution of $1.54 per share compared with an as adjusted net tangible book value of $0.31.
The company is an emerging growth, clinical‑stage ophthalmology biotech focused on urcosimod for neuropathic corneal pain and dry eye disease. Its ordinary shares trade on the Nasdaq Capital Market under the symbol “OKYO,” and the offering is underwritten on a firm commitment basis by Piper Sandler.
OKYO Pharma Limited is conducting a primary offering of ordinary shares on The Nasdaq Capital Market under its F-3 shelf registration. The shares will be sold through an underwritten public offering led by Piper Sandler, with an additional 30-day option for underwriters to buy more shares.
OKYO expects to use the net proceeds for clinical development of its product candidates, general corporate purposes and working capital. As an emerging growth company, it follows reduced reporting requirements and warns investors about high investment risk, potential dilution from this and future equity issuances, and the possibility of Nasdaq delisting if listing standards are not maintained.
OKYO Pharma Limited is establishing an at-the-market program to sell up to $50 million of ordinary shares through Leerink Partners on Nasdaq under the symbol OKYO.
Leerink Partners will act as sales agent or principal and earn a 3% commission on gross proceeds. Based on an illustrative price of $1.99, the company shows a scenario where shares outstanding could rise from 40,555,197 to up to 65,680,825, highlighting potential dilution for new and existing holders.
OKYO plans to use any net proceeds for clinical development, general corporate purposes and working capital, with a primary focus on advancing its lead drug candidate urcosimod for neuropathic corneal pain, an indication with no FDA‑approved therapies. Urcosimod has Fast Track designation and encouraging Phase 2a and dry eye disease data, but the company notes significant risks, including ongoing losses, future financing needs, and the possibility of Nasdaq delisting.